儿童癌症生物标记市场－全球产业规模、份额、趋势、机会及预测（按适应症、类型、最终用途、地区和竞争格局划分，2021-2031年）

全球儿童癌症生物标记市场预计将从 2025 年的 8.1553 亿美元大幅成长至 2031 年的 13.9378 亿美元，复合年增长率达到 9.34%。

儿童癌症生物标记，包括特定的生物分子和基因突变，是诊断、预测预后和监测儿童恶性肿瘤治疗效果的重要工具。推动这一市场成长的主要因素是精准肿瘤学的日益普及，其旨在基于精确的分子谱分析实现个体化治疗，从而最大限度地减少对发育中生理功能的长期副作用。此外，微创诊断技术（例如液态生物检体）的兴起也促进了市场发展，与传统的组织切片检查相比，液体活检能够提供更快捷的检测方法。

儘管取得了这些进展，但该领域仍面临着许多挑战，例如儿童肿瘤样本的有限性和儿童癌症的生物学复杂性等因素阻碍了全面的临床检验。统计数据凸显了此类诊断解决方案的迫切需求：根据美国癌症研究协会（AACR）预测，到2025年，全球每年将有约40万名儿童罹患癌症。如此沉重的负担凸显了开发可靠的生物标誌物的紧迫性，然而，招募足够的儿童患者群体以获得监管部门核准所面临的后勤挑战仍然是快速商业化的主要瓶颈。

市场驱动因素

精准医疗的加速发展正在从根本上改变市场格局，它优先考虑特定的分子谱分析，而非广泛的干预措施。随着临床医生越来越多地利用基因组数据来检测可治疗的突变，能够指导免疫疗法和激酶抑制剂选择的检测需求也随之飙升。这项转变旨在改善復发或难治性癌症儿童的治疗效果，同时降低传统化疗带来的毒性。美国癌症研究协会 (AACR) 于 2025 年 12 月发布的《2025 年 AACR儿童癌症进展报告》也印证了这一趋势。报告指出，2015 年至 2025 年间，美国食品药物管理局 (FDA)核准了20 多种分子标靶疗法和 10 多种免疫疗法用于治疗儿童癌症，并强调了生物标誌物在为患者匹配这些先进疗法方面的重要性日益凸显。

同时，政府拨款和学术津贴的增加为降低儿童专用诊断工具研发风险提供了必要的资金。由于儿童肿瘤领域规模小于成人市场，公共部门的支持对于支付生物标记发现和检验的高昂成本至关重要。例如，美国国立卫生研究院 (NIH) 于 2025 年 9 月宣布，将把其儿童癌症数据倡议的年度预算增加一倍，达到 1 亿美元，以加快数据生成和分析。此外，消除全球差异仍然是重点关注的问题。世界卫生组织 (WHO) 2025 年的报告预测，高所得国家的存活率将超过 80%，而中低收入国家的存活率仍低于 30%，这凸显了开发经济有效的生物标记解决方案以改善全球早期诊断的紧迫性。

市场挑战

全球儿童癌症生物标记市场成长的主要障碍在于儿童肿瘤样本的稀缺性以及这些癌症固有的生物学异质性。与成人恶性肿瘤相比，儿童癌症较为罕见，具有独特的生物学特征，并且通常具有独特的基因突变，这些突变在不同患者之间差异显着。这种多样性要求进行广泛的研究来验证新型生物标记的临床疗效，但高品质组织样本的有限供应使得获取监管申报所需的具有统计意义的数据变得极其困难。因此，诊断公司面临着漫长的研发週期和不断上涨的成本，抑制了投资并延缓了精准检测平台的应用。

这项根本限制严重限制了市场参与企业快速拓展产品系列的能力。对于这些发生率低于成人癌症的疾病而言，招募足够的受试者尤其困难。根据美国癌症协会估计，2024年美国将有9,620名0至14岁的儿童被诊断出罹患癌症。如此小规模的患者群体在临床试验招募方面造成了严重的瓶颈，直接阻碍了新型生物标记的检验，并最终减缓了整体市场扩张。

市场趋势

微小残留疾病（MRD）检测的广泛应用已成为一项重要的市场趋势，其驱动力在于对更高灵敏度的治疗反应评估和復发预测的需求。除了传统的形态学评估外，先进的MRD检测已成为临床试验和监管核准的重要组成部分，并经常被用作检验新型疗法疗效的主要终点。 MRD状态在骨髓恶性肿瘤治疗策略指南中的应用日益广泛，也印证了这一发展趋势。例如，亚盛医药在2025年12月发布的新闻稿中宣布，FDA和EMA核准了其针对新诊断的Ph+ ALL患者的3期POLARIS-1试验。新闻稿指出，该公司联合治疗在三个疗程后实现了约65%的分子MRD阴性率，凸显了检测在证明新型药物临床价值方面发挥的关键作用。

同时，功能性精准医学检测的兴起标誌着治疗评估方式正从静态基因组分析转向动态评估，包括药物敏感性和暴露程度。这些功能性生物标记能够帮助临床医生优化给药方案，并降低因药物浓度不足而导致的復发风险。对转化研究的大量投入正推动着这些标誌物的检验。值得注意的是，2024年12月，纪念斯隆-凯特琳癌症中心在《MSK Kids 2024：儿童癌症临床和研究进展亮点》报告中指出，该中心已获得美国国防部440万美元的津贴，用于开展INFLUENCE试验。该试验利用功能性检测来接受儿童白血病患者的復发风险。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球儿童癌症生物标记市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 根据适应症（白血病、神经母细胞瘤、中枢神经系统肿瘤、淋巴瘤、其他）
  • 依类型（胎儿球蛋白(AFP)、神经元特异性烯醇化酶 (NSE)、CD19、CD20、CD22、ALK（间变性淋巴瘤受体蛋白酪氨酸激酶基因）、其他）
  • 透过申请（医院、诊断检查室、肿瘤中心、研究机构）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美儿童癌症生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲儿童癌症生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区儿童癌症生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲儿童癌症生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美儿童癌症生物标记市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球儿童癌症生物标记市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Roche Diagnostics
• Thermo Fisher Scientific
• Qiagen
• Abbott
• Illumina
• Bio-Rad
• Myriad Genetics
• Agilent
• Roche
• Takara Bio

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pediatric Cancer Biomarkers Market is projected to expand significantly, growing from USD 815.53 Million in 2025 to USD 1393.78 Million by 2031, achieving a compound annual growth rate of 9.34%. Pediatric cancer biomarkers, which encompass specific biological molecules or genetic alterations, are essential tools for diagnosing, prognosing, and monitoring therapeutic responses in childhood malignancies. A primary engine of this growth is the increasing integration of precision oncology, which relies on accurate molecular profiling to customize treatments and minimize long-term adverse effects in developing physiologies. Furthermore, the market is being bolstered by a shift toward minimally invasive diagnostic techniques, such as liquid biopsies, which offer faster testing alternatives compared to conventional tissue biopsies.

Despite these advancements, the sector faces substantial obstacles due to the rarity of pediatric tumor samples and the biological complexity of childhood cancers, both of which impede comprehensive clinical validation. Statistical data underscores the critical necessity for these diagnostic solutions; according to the American Association for Cancer Research, approximately 400,000 children globally are expected to develop cancer annually in 2025. While this heavy burden highlights the urgent requirement for robust biomarker development, the logistical challenges associated with recruiting sufficient pediatric patient cohorts for regulatory approval continue to act as a major bottleneck to rapid commercialization.

Market Driver

The market is being fundamentally transformed by an accelerated transition toward precision medicine, which prioritizes specific molecular profiling over broad-spectrum interventions. As clinicians increasingly utilize genomic data to detect actionable alterations, there is a surging demand for assays capable of guiding the selection of immunotherapies and kinase inhibitors. This shift aims to lower the toxicity linked to traditional chemotherapy while enhancing outcomes for young patients with relapsed or refractory conditions. The "AACR Pediatric Cancer Progress Report 2025," released by the American Association for Cancer Research in December 2025, validates this trend by noting that the FDA approved over 20 molecularly targeted therapies and more than 10 immunotherapies for pediatric cancers between 2015 and 2025, highlighting the growing reliance on biomarkers to match patients with these advanced treatments.

Concurrently, increased government funding and academic grants are supplying the necessary capital to mitigate risks associated with developing pediatric-specific diagnostic tools. Given that the pediatric oncology sector is smaller than the adult market, public sector backing is vital for covering the substantial costs of biomarker discovery and validation. For instance, the National Institutes of Health announced in September 2025 that it would double the annual budget for the Childhood Cancer Data Initiative to $100 million to expedite data generation and analysis. Additionally, addressing global disparities remains a key focus; according to the World Health Organization in 2025, survival rates exceed 80% in high-income countries but remain below 30% in low- and middle-income nations, emphasizing the urgent need for cost-effective biomarker solutions to enhance early diagnosis globally.

Market Challenge

A primary obstacle impeding the growth of the Global Pediatric Cancer Biomarkers Market is the scarcity of pediatric tumor samples combined with the inherent biological heterogeneity of these cancers. In contrast to adult malignancies, childhood cancers are rare and biologically distinct, often characterized by unique genetic alterations that vary significantly among patients. This diversity requires extensive studies to prove the clinical validity of new biomarkers, yet the limited supply of high-quality tissue samples makes it extremely challenging to produce the statistically significant data needed for regulatory submissions. As a result, diagnostic companies encounter extended development timelines and increased costs, factors that deter investment and delay the introduction of precision testing platforms.

This fundamental constraint severely limits the capacity of market participants to rapidly broaden their product portfolios. The challenge of recruiting sufficient study cohorts is highlighted by the low incidence rates of these conditions relative to adult cancers. According to the American Cancer Society, an estimated 9,620 children aged birth to 14 years were diagnosed with cancer in the United States in 2024. This comparatively small patient population creates a significant bottleneck for clinical trial recruitment, which directly hampers the validation of novel biomarkers and consequently stalls the overall expansion of the market.

Market Trends

The widespread adoption of Minimal Residual Disease (MRD) testing is emerging as a critical market trend, driven by the necessity to evaluate treatment efficacy and predict relapse with superior sensitivity. Moving beyond traditional morphological assessments, advanced MRD assays have become essential components of clinical trials and regulatory approvals, frequently serving as primary endpoints for validating new therapeutics. This evolution is illustrated by the growing use of MRD status to direct treatment strategies in hematologic malignancies. For example, in December 2025, Ascentage Pharma reported in its press release regarding the "FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL" that its combination therapy achieved a molecular MRD-negativity rate of roughly 65% after three cycles, underscoring the test's pivotal role in proving the clinical value of new drugs.

Simultaneously, the rise of Functional Precision Medicine Assays represents a move beyond static genomic profiling toward the evaluation of dynamic therapeutic responses, including drug sensitivity and exposure levels. These functional biomarkers enable clinicians to refine dosing regimens and reduce relapse risks associated with inadequate drug concentrations. The momentum to validate these markers is bolstered by significant investment in translational research. A notable example occurred in December 2024, when Memorial Sloan Kettering Cancer Center reported in its "MSK Kids 2024: Highlights of Clinical and Research Advances for Pediatric Cancers" that it had received a $4.4 million grant from the U.S. Department of Defense for the INFLUENCE Trial, which employs functional assays to address relapse risks in pediatric leukemia patients.

Key Market Players

• Roche Diagnostics
• Thermo Fisher Scientific
• Qiagen
• Abbott
• Illumina
• Bio-Rad
• Myriad Genetics
• Agilent
• Roche
• Takara Bio

Report Scope

In this report, the Global Pediatric Cancer Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Cancer Biomarkers Market, By Indication

• Leukemia
• Neuroblastoma
• CNS Tumors
• Lymphoma
• Others

Pediatric Cancer Biomarkers Market, By Type

• Alpha-fetoprotein (AFP)
• Neuron-specific enolase (NSE)
• CD19
• CD20
• CD22
• ALK (anaplastic lymphoma receptor tyrosine kinase gene)
• Others

Pediatric Cancer Biomarkers Market, By End-Use

• Hospital
• Diagnostic Laboratories
• Oncology Centers
• Research Institutions

Pediatric Cancer Biomarkers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Cancer Biomarkers Market.

Available Customizations:

Global Pediatric Cancer Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Cancer Biomarkers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma, Others)
  • 5.2.2. By Type (Alpha-fetoprotein (AFP), Neuron-specific enolase (NSE), CD19, CD20, CD22, ALK (anaplastic lymphoma receptor tyrosine kinase gene), Others)
  • 5.2.3. By End-Use (Hospital, Diagnostic Laboratories, Oncology Centers, Research Institutions)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pediatric Cancer Biomarkers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Type
  • 6.2.3. By End-Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Cancer Biomarkers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Canada Pediatric Cancer Biomarkers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Mexico Pediatric Cancer Biomarkers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End-Use

7. Europe Pediatric Cancer Biomarkers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Type
  • 7.2.3. By End-Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Cancer Biomarkers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End-Use
  • 7.3.2. France Pediatric Cancer Biomarkers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom Pediatric Cancer Biomarkers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy Pediatric Cancer Biomarkers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain Pediatric Cancer Biomarkers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End-Use

8. Asia Pacific Pediatric Cancer Biomarkers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Type
  • 8.2.3. By End-Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pediatric Cancer Biomarkers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India Pediatric Cancer Biomarkers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End-Use
  • 8.3.3. Japan Pediatric Cancer Biomarkers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End-Use
  • 8.3.4. South Korea Pediatric Cancer Biomarkers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia Pediatric Cancer Biomarkers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End-Use

9. Middle East & Africa Pediatric Cancer Biomarkers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Type
  • 9.2.3. By End-Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pediatric Cancer Biomarkers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End-Use
  • 9.3.2. UAE Pediatric Cancer Biomarkers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End-Use
  • 9.3.3. South Africa Pediatric Cancer Biomarkers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End-Use

10. South America Pediatric Cancer Biomarkers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Type
  • 10.2.3. By End-Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pediatric Cancer Biomarkers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Colombia Pediatric Cancer Biomarkers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End-Use
  • 10.3.3. Argentina Pediatric Cancer Biomarkers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pediatric Cancer Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Roche Diagnostics
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific
• 15.3. Qiagen
• 15.4. Abbott
• 15.5. Illumina
• 15.6. Bio-Rad
• 15.7. Myriad Genetics
• 15.8. Agilent
• 15.9. Roche
• 15.10. Takara Bio

16. Strategic Recommendations

17. About Us & Disclaimer